Antihypertensive therapy in the presence of proteinuria.
about
Carvedilol in hypertension treatmentAntihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemSulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature reviewElectronic problem list documentation of chronic kidney disease and quality of careAvosentan for overt diabetic nephropathy.CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study.Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).Hypertensive nephropathy: prevention and treatment recommendations.Advances in treatment of hyperkalemia in chronic kidney disease.Systolic blood pressure and outcomes in stage 3-4 chronic kidney disease patients: evidence from a Taiwanese cohort.Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients.Automated clinical reminders for primary care providers in the care of CKD: a small cluster-randomized controlled trialCorticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.High prevalence of isolated nocturnal hypertension in Chinese patients with chronic kidney disease.Diagnostic potential for urinary proteomics.Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complicationsTreatment of hypertension in children and adolescents.Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.Lessons from ONTARGET.Matrix Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation.Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease.Effect of telmisartan on kidney function in patients with chronic kidney disease: an observational study.Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds.Renal function and target organ damage in hypertension.Resistant hypertension: concepts and approach to management.Renal complications of diabetes.Fenofibrate and the kidney: an overview.How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?IgG4-related disease and the kidney.Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression.A Quantitative Systems Physiology Model of Renal Function and Blood Pressure Regulation: Application in Salt-Sensitive HypertensionThe Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes.Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.A review of chemical therapies for treating diabetic hypertension.Prevalence, determinants, and clinical significance of masked hypertension and white-coat hypertension in patients with chronic kidney disease.Recent trends in the prevalence of chronic kidney disease in Korean adults: Korean National Health and Nutrition Examination Survey from 1998 to 2013.Low α-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction.
P2860
Q24642654-C46CC967-9D13-4C80-A9B5-A218859177C3Q26865691-E79DB09E-BC97-478E-8AF8-E0DC1EA07220Q28083781-E47911A0-142F-48B6-89BA-66B77271EA51Q33613413-A9039CF1-17F4-479F-BA93-3F1557BCD61EQ33702404-148C8C19-287B-4BB3-BF43-3C205080BD66Q33984240-B456D5E9-F931-478E-9DD2-F54674CBB786Q33988764-A1917AC5-4B73-4591-847A-FA7A8B1A8C10Q33988780-D5E33396-9401-46EF-AECD-8F2103961412Q34131899-2073A843-8121-4CF1-A18F-972E5AC1AD11Q34491934-D9E80841-E785-45FB-A2A1-A3833FF5854CQ34683689-F4B027EE-C133-4E1C-ADA9-74CE75CA2D56Q34686870-C6AC0002-4253-4F62-B33F-BC501CD9D91DQ35210549-184F9F08-A83C-48AD-A7A1-A3A16CE089F9Q35566672-7B7390E3-8AA9-4BA5-9938-DCEE7B9AE4EDQ36077744-A99C9EBA-E003-43E9-A26F-1E006A6FCAC1Q36126918-82A9ADF5-0065-4DB8-A522-FBC762696BA3Q36142032-BEDE8D64-6FEE-438F-B40B-646AD09A8C98Q36745677-D229A2B1-7114-42FE-A967-D32641F0FFE4Q36828612-387842C2-2631-46A7-A6B0-D393252CD9AEQ36906732-A02F12C0-3897-4145-8663-466B61E784B6Q37158325-49A89D31-BBF5-4677-B590-0A7F587F197DQ37247749-799C6290-F44D-4A4D-87D4-59B18D29BFE8Q37364008-80B3C15C-F792-40D4-B8BB-E4BEE0C02F99Q37416129-1609220F-F1ED-4028-986F-57D47F3BC708Q37471906-D43B0813-E76C-4862-A9F1-F4B9DC80EAF7Q37679932-989EB639-8668-4FD0-BE24-7FCA5216469DQ37858832-7733C239-01F4-427F-B13E-F591C666267BQ37933093-C974AF33-4906-4A59-AB96-A213021D733CQ38057180-EB3BCFB8-7B0F-49CB-9429-EF23A60655C1Q38088377-08001A0B-FD57-42B7-AC72-B7B5919C1A21Q38191126-5E9A867D-BD1D-45A0-BC3D-0DB24FF5D601Q38540095-DC059624-9251-42B0-9A33-C63E55FA6177Q38553935-3489051F-D625-4CB2-A5F6-6B8283B31301Q38757176-E3DB676B-429B-4A06-BEA6-5101B256D6BBQ38940749-205497DD-93EC-4028-8CDB-D3215092BE99Q38999373-B31D7C83-02C2-452E-884D-EDA0978F06AAQ39290260-9E1CACBE-707D-46A8-AD12-605246FA0A3BQ40322846-40006273-053E-46F4-9740-0B05629DC918Q40516396-793933E8-0A64-4201-9A06-58677B3152C9Q40630909-0602D7D2-B63B-4178-8CDA-78204E836B51
P2860
Antihypertensive therapy in the presence of proteinuria.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antihypertensive therapy in the presence of proteinuria.
@ast
Antihypertensive therapy in the presence of proteinuria.
@en
type
label
Antihypertensive therapy in the presence of proteinuria.
@ast
Antihypertensive therapy in the presence of proteinuria.
@en
prefLabel
Antihypertensive therapy in the presence of proteinuria.
@ast
Antihypertensive therapy in the presence of proteinuria.
@en
P2093
P1476
Antihypertensive therapy in the presence of proteinuria.
@en
P2093
George L Bakris
Nitin Khosla
Pantelis A Sarafidis
P356
10.1053/J.AJKD.2006.10.014
P577
2007-01-01T00:00:00Z